Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA grants orphan drug designation to resveratrol formulation in MELAS syndrome

April 3, 2008

Acadia initiates second phase III trial of pimavanserin for Parkinson's disease psychosis

April 3, 2008

Elite presents update on abuse-resistant pain products

April 3, 2008

Cysteine protease inhibitors reduce beta-amyloid, improve memory in Alzheimer's model

April 2, 2008

New agents for treating neurological disorders disclosed in recent patents

April 2, 2008

Synosia Therapeutics commences phase II rufinamide trial for general anxiety disorder

April 1, 2008

NeuroSearch initiates phase I NSD-788 study for anxiety and depression

April 1, 2008

Lilly commences phase III LY-450139 trial for Alzheimer's disease

April 1, 2008

DJ-1 provides neuroprotection against oxidative stress

April 1, 2008

Recent Amgen and Kyowa Hakko patents disclose novel analgesic agents

April 1, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...